Skip to main content
. 2020 Apr 13;11(6):1541–1549. doi: 10.1111/1759-7714.13426

Table 1.

Clinical characteristics of all study subjects

Variable, n (%)
Age, median (year) 64 (52–74)
Gender
Male 26 (83.9)
Female 5 (16.1)
Smoking status
Smoker/ex‐smoker 23 (74.2)
Never smoker 8 (25.8)
ECOG PS
0 25 (80.7)
1 5 (16.1)
2 1 (3.2)
Histology
Adenocarcinoma 20 (64.5)
Squamous cell carcinoma 8 (25.8)
NSCLC NOS 3 (9.7)
Staging
IIIA 8 (25.8)
IIIB 21 (67.7)
IIIC 2 (6.5)
EGFR mutation status
Mutated EGFR 4 (12.9)
Wild type 19 (61.3)
Unknown 8 (25.8)
ALK fusion status
Positive 1 (3.3)
Negative 17 (54.8)
Unknown 13 (41.9)
PD‐L1 TPS
Positive (≥1%) 14 (45.2)
Negative (<1%) 6 (19.3)
Unknown 11 (35.5)
Chemotherapy regimen
Docetaxel plus cisplatin 13 (41.9)
Vinorelbine plus cisplatin 18 (58.1)
Dose of radiotherapy
60–66 Gy 23 (74.2)
>66 Gy 8 (25.8)
Timing of durvalumab initiation post‐CCRT, median (month) 2.8 (1.8–3.7)
Total 31 (100.0)

ALK, anaplastic lymphoma kinase; CCRT, concurrent chemoradiation; ECOG PS, Eastern Cooperative Oncology Group performance status; EGFR, epidermal growth factor receptor; NOS, not otherwise specified; PD‐L1, Programmed death‐ligand 1; TPS, tumor proportion score.